basic information
mesothelioma & asbestos
mesothelioma treatment
mesothelioma research

mesothelioma cancer
malignant mesothelioma
peritoneal mesothelioma
pleural mesothelioma
malignant pleural mesothelioma

picking an attorney
mesothelioma lawyers
settlement examples
asbestos litigation
abuse of lawsuits

news articles
clinical research







Mesothelioma Clinical Trials

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

This study is currently recruiting patients.

Sponsored by

Ottawa Regional Cancer Centre
For more information:National Cancer Institute (NCI)

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Hormone therapy using tamoxifen may fight cancer by blocking the uptake of estrogen. Combining tamoxifen and chemotherapy may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of cisplatin and doxorubicin plus tamoxifen in treating patients who have solid tumors.

Condition Treatment or Intervention
 Drug: cisplatin
 Drug: doxorubicin
 Drug: tamoxifen
 Procedure: antiestrogen therapy
 Procedure: chemotherapy
 Procedure: conventional surgery
 Procedure: drug modulation
 Procedure: endocrine therapy
 Procedure: hormone therapy
 Procedure: radiation therapy
 Procedure: surgery

This is a Phase II test

  • In Phase II clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.  

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of Cisplatin, Doxorubicin, and Tamoxifen (CAT) in Patients With Incurable Soft Tissue Sarcoma, Glioma, Mesothelioma, Hepatoma, Thyroid Cancer, or Adrenal Cancer

Further Study Details: 


  • Determine the feasibility and efficacy of cisplatin, doxorubicin, and tamoxifen (CAT) in patients with soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer.
  • Determine the toxicity of this regimen in these patients.

OUTLINE: Patients receive cisplatin IV over 1-2 hours followed immediately by doxorubicin IV over 15-30 minutes on days 1-3 and oral tamoxifen twice daily on days 4-17. Treatment continues every 3 weeks in the absence of the total cumulative doxorubicin dose reaching at least 500 mg/m2, disease progression, or unacceptable toxicity. Patients who achieve partial remission (PR) undergo local surgery or radiotherapy, if feasible, to convert PR to complete remission.

Patients are followed every 2 months for 1 year and then every 3 months for 2 years.

PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study.

Ages Eligible for Study:  up to  65 Years,  Genders Eligible for Study:  Both



  • Histologically proven soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer with clinical, radiological, or histologic evidence of incurability
  • Patients with thyroid cancer must have failed radioactive iodine
  • Measurable or evaluable disease 

Privacy    Terms of Use & Copyright    Home   

Contact Us